Ocugen completes dosing in second cohort of Phase 1/2 GARDian trial for OCU410ST

Ocugen announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST, a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life. Six patients with Stargardt disease have been dosed in the Phase 1/2 clinical trial to date. An additional three patients will be dosed with the high dose (Cohort 3) of OCU410ST in the dose-escalation phase. A Data and Safety Monitoring Board meeting will convene next month to review the 4-week safety data of the medium dose cohort before proceeding with Cohort 3 (high dose), which is the final dose in the Phase 1 dose-escalation study. The company expects to provide a clinical trial update for OCU410ST in the third quarter of 2024.